Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Breast Neoplasms 1Blast Crisis 1Anemia 1

Interventions

Cyclophosphamide 125fludarabine phosphate 116Busulfan 98Peripheral Blood Stem Cell Transplantation 88Filgrastim 73Antilymphocyte Serum 72Tacrolimus 67Cytarabine 67Cyclosporine 64Mycophenolic Acid 63Methotrexate 57Radiotherapy 54fludarabine 52Whole-Body Irradiation 52Melphalan 49Imatinib Mesylate 41Azacitidine 35Methylprednisolone 34Etoposide 33Cord Blood Stem Cell Transplantation 30Granulocyte Colony-Stimulating Factor 28sargramostim 26Thiotepa 26Decitabine 21Alemtuzumab 21Clofarabine 20thymoglobulin 19Stem Cell Transplantation 19nilotinib 18Interferon-alpha 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Erlotinib Hydrochloride × Myeloid × Clear all
NCT00977548 2013-09-16

Erlotinib Study for Myelodysplastic Syndrome (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
39 enrolled 10 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡